1. Home
  2. CHCO vs RAPP Comparison

CHCO vs RAPP Comparison

Compare CHCO & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo City Holding Company

CHCO

City Holding Company

HOLD

Current Price

$132.05

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$41.71

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHCO
RAPP
Founded
1957
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
1995
2024

Fundamental Metrics

Financial Performance
Metric
CHCO
RAPP
Price
$132.05
$41.71
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$132.50
$48.50
AVG Volume (30 Days)
130.1K
359.4K
Earning Date
04-23-2026
05-08-2026
Dividend Yield
2.87%
N/A
EPS Growth
13.18
24.34
EPS
2.20
N/A
Revenue
N/A
N/A
Revenue This Year
$5.16
N/A
Revenue Next Year
$3.12
N/A
P/E Ratio
$59.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$113.21
$11.33
52 Week High
$134.92
$42.27

Technical Indicators

Market Signals
Indicator
CHCO
RAPP
Relative Strength Index (RSI) 62.35 63.58
Support Level $120.29 $33.54
Resistance Level N/A N/A
Average True Range (ATR) 2.85 2.50
MACD 0.37 0.36
Stochastic Oscillator 71.02 78.23

Price Performance

Historical Comparison
CHCO
RAPP

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: